Human recombinant soluble ACE2 in severe COVID-19
…, T Seitz, M Traugott, A Grieb, E Pawelka… - The Lancet …, 2020 - thelancet.com
Angiotensin converting enzyme 2 (ACE2) is the crucial severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) receptor and protects multiple tissues, including the lung, from …
coronavirus 2 (SARS-CoV-2) receptor and protects multiple tissues, including the lung, from …
Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2
…, O Pich, W Borena, E Pawelka… - Science translational …, 2020 - science.org
Superspreading events shaped the coronavirus disease 2019 (COVID-19) pandemic, and
their rapid identification and containment are essential for disease control. Here, we provide a …
their rapid identification and containment are essential for disease control. Here, we provide a …
SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses
…, W Weninger, G Fischer, W Hoepler, E Pawelka… - Science …, 2021 - science.org
CD8 + T cell immunity to SARS-CoV-2 has been implicated in COVID-19 severity and virus
control. Here, we identified nonsynonymous mutations in MHC-I-restricted CD8 + T cell …
control. Here, we identified nonsynonymous mutations in MHC-I-restricted CD8 + T cell …
COVID‐19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission
…, O Malle, A Oulhaj, E Pawelka… - Diabetes, Obesity …, 2021 - Wiley Online Library
… This study captured and processed data using an electronic case report form developed
with HybridForms, as part of a validated electronic data capture system with an audit trail and …
with HybridForms, as part of a validated electronic data capture system with an audit trail and …
Muscle involvement in SARS‐CoV‐2 infection
…, JV Wanschitz, C Horlings, E Pawelka… - European journal of …, 2021 - Wiley Online Library
Background and Purpose Since the outbreak of the severe acute respiratory syndrome
coronavirus‐2 (SARS‐CoV‐2) pandemic, several reports indicated neurological involvement in …
coronavirus‐2 (SARS‐CoV‐2) pandemic, several reports indicated neurological involvement in …
Performance of severe acute respiratory syndrome coronavirus 2 antibody assays in different stages of infection: comparison of commercial enzyme-linked …
…, E Pawelka, E Puchhammer-Stöckl… - The Journal of …, 2020 - academic.oup.com
We comparatively assessed sensitivities and specificities of 4 commercial enzyme-linked
immunosorbent assays (ELISAs) and 2 rapid tests in 77 patients with polymerase chain …
immunosorbent assays (ELISAs) and 2 rapid tests in 77 patients with polymerase chain …
Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays
…, T Seitz, H Kelani, M Karolyi, E Pawelka… - Journal of clinical …, 2021 - Am Soc Microbiol
In this study, we comprehensively analyzed multispecific antibody kinetics of different
immunoglobulins in hospitalized patients with acute severe acute respiratory syndrome …
immunoglobulins in hospitalized patients with acute severe acute respiratory syndrome …
[HTML][HTML] Platelet phenotype analysis of COVID-19 patients reveals progressive changes in the activation of integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and …
…, D Pereyra, J Santol, E Pawelka… - Frontiers in …, 2021 - frontiersin.org
Background: The fatal consequences of an infection with severe acute respiratory syndrome
coronavirus 2 are not only caused by severe pneumonia, but also by thrombosis. Platelets …
coronavirus 2 are not only caused by severe pneumonia, but also by thrombosis. Platelets …
Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study
…, T Sorz, F Fritsch, H Hayden, E Pawelka… - Cardiovascular …, 2021 - academic.oup.com
Aims Anticoagulation was associated with improved survival of hospitalized coronavirus
disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-…
disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-…
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
M Karolyi, E Pawelka, T Mader, S Omid… - Wiener Klinische …, 2021 - Springer
… Incomplete data were updated retrospectively from patient electronic health records
whenever possible. … Erich Pawelka … Pawelka contributed equally to the manuscript. …
whenever possible. … Erich Pawelka … Pawelka contributed equally to the manuscript. …